Amgen cholesterol drug reduces artery-clogging plaque in study

NEW ORLEANS (Reuters) - Amgen Inc's potent new drug Repatha, when added to statin therapy, not only took "bad" LDL cholesterol down to extremely low levels but caused declines in artery-clogging plaque in a majority of high-risk heart patients after 18 months of treatment, according to data from a clinical trial.